Dr. Padua has 156 years of experience in the medical device industry. He has participated in research projects to administer preclinical studies as well as pre- and post-market clinical studies.
St. Teresa is moving forward with commercialization of its new hemostatic technology platform — ORTHOCLOT — and Dr. Padua will play a central role in developing and executing the clinical plan and procedures for the human trial in Europe.
More articles on orthopedic devices:
Exactech director sells 8k shares in $410k transaction
Medtronic tax inversion strategy profitable for two top Republicans
Medtech investment: 8 observations on future growth
